Becton Dickinson and Co (NYSE:BDX) has been assigned an average rating of “Buy” from the fifteen analysts that are currently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $251.08.

BDX has been the topic of a number of recent research reports. KeyCorp reissued a “buy” rating and set a $264.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. ValuEngine raised Becton Dickinson and from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. Citigroup lifted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. Royal Bank of Canada reissued a “hold” rating and set a $248.00 price target on shares of Becton Dickinson and in a research note on Friday, August 3rd. Finally, Wells Fargo & Co lifted their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call.

Becton Dickinson and stock traded down $1.67 during midday trading on Friday, reaching $259.99. The company’s stock had a trading volume of 490,900 shares, compared to its average volume of 1,167,768. Becton Dickinson and has a 52 week low of $192.66 and a 52 week high of $264.47. The stock has a market cap of $70.15 billion, a PE ratio of 27.43, a P/E/G ratio of 1.79 and a beta of 1.10. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 EPS for the quarter, beating the Zacks’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a return on equity of 14.16% and a net margin of 4.73%. The firm had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same period last year, the firm posted $2.46 earnings per share. The business’s revenue for the quarter was up 41.0% on a year-over-year basis. analysts expect that Becton Dickinson and will post 11.01 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Friday, September 7th will be paid a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

Several institutional investors have recently bought and sold shares of the stock. United Services Automobile Association lifted its stake in shares of Becton Dickinson and by 5.8% in the second quarter. United Services Automobile Association now owns 118,770 shares of the medical instruments supplier’s stock worth $28,453,000 after acquiring an additional 6,541 shares during the period. Rehmann Capital Advisory Group lifted its stake in shares of Becton Dickinson and by 25.1% in the second quarter. Rehmann Capital Advisory Group now owns 1,912 shares of the medical instruments supplier’s stock worth $458,000 after acquiring an additional 384 shares during the period. Royal London Asset Management Ltd. acquired a new position in shares of Becton Dickinson and in the second quarter worth approximately $26,089,000. FMR LLC lifted its stake in shares of Becton Dickinson and by 7.6% in the second quarter. FMR LLC now owns 16,067,452 shares of the medical instruments supplier’s stock worth $3,849,118,000 after acquiring an additional 1,129,688 shares during the period. Finally, Mainstay Capital Management LLC ADV lifted its stake in shares of Becton Dickinson and by 8,211.2% in the second quarter. Mainstay Capital Management LLC ADV now owns 97,989 shares of the medical instruments supplier’s stock worth $611,000 after acquiring an additional 96,810 shares during the period. 92.47% of the stock is currently owned by institutional investors.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Article: Market Capitalization in the Stock Market

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.